| pubmed-article:10848516 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10848516 | lifeskim:mentions | umls-concept:C0452875 | lld:lifeskim |
| pubmed-article:10848516 | lifeskim:mentions | umls-concept:C0013273 | lld:lifeskim |
| pubmed-article:10848516 | lifeskim:mentions | umls-concept:C0521457 | lld:lifeskim |
| pubmed-article:10848516 | lifeskim:mentions | umls-concept:C1257954 | lld:lifeskim |
| pubmed-article:10848516 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:10848516 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:10848516 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10848516 | pubmed:dateCreated | 2000-7-6 | lld:pubmed |
| pubmed-article:10848516 | pubmed:abstractText | Nonselective cyclooxygenase (COX) inhibitors are potent tocolytic agents; however, they also have adverse fetal effects such as constriction of the fetal ductus arteriosus. Recently, selective COX-2 inhibitors have been used in the management of preterm labor in the hope of avoiding fetal complications. However, both COX-1 and -2 are expressed by cells of the ductus arteriosus. We used fetal lambs (0.88 gestation) to assess the ability of selective COX-2 inhibitors celecoxib and NS398 to affect the ductus arteriosus. Both selective COX-2 inhibitors decreased PGE(2) and 6ketoPGF(1alpha) production in vitro; both inhibitors constricted the isolated ductus in vitro. The nonselective COX-1/COX-2 inhibitor indomethacin produced a further reduction in PG release and an additional increase in ductus tension in vitro. We used a prodrug of celecoxib to achieve 1.4 +/- 0.6 microg/ml, mean +/- standard deviation, of the active drug in vivo. This concentration of celecoxib produced both an increase in pressure gradient and resistance across the ductus; celecoxib also decreased fetal plasma concentrations of PGE(2) and 6ketoPGF(1alpha). Indomethacin (0.7 +/- 0.2 microg/ml) produced a significantly greater fall in ductus blood flow than celecoxib and tended to have a greater effect on ductus resistence in vivo. We conclude that caution should be used when recommending COX-2 inhibitors for use in pregnant women, because COX-2 appears to play a significant role in maintaining patency of the fetal ductus arteriosus. | lld:pubmed |
| pubmed-article:10848516 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10848516 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10848516 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10848516 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:10848516 | pubmed:issn | 0363-6119 | lld:pubmed |
| pubmed-article:10848516 | pubmed:author | pubmed-author:HeymannM AMA | lld:pubmed |
| pubmed-article:10848516 | pubmed:author | pubmed-author:TakahashiYY | lld:pubmed |
| pubmed-article:10848516 | pubmed:author | pubmed-author:ClymanR IRI | lld:pubmed |
| pubmed-article:10848516 | pubmed:author | pubmed-author:LiuLL | lld:pubmed |
| pubmed-article:10848516 | pubmed:author | pubmed-author:RomanCC | lld:pubmed |
| pubmed-article:10848516 | pubmed:author | pubmed-author:ChemtobSS | lld:pubmed |
| pubmed-article:10848516 | pubmed:author | pubmed-author:TseM MMM | lld:pubmed |
| pubmed-article:10848516 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10848516 | pubmed:volume | 278 | lld:pubmed |
| pubmed-article:10848516 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10848516 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10848516 | pubmed:pagination | R1496-505 | lld:pubmed |
| pubmed-article:10848516 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:meshHeading | pubmed-meshheading:10848516... | lld:pubmed |
| pubmed-article:10848516 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10848516 | pubmed:articleTitle | Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. | lld:pubmed |
| pubmed-article:10848516 | pubmed:affiliation | Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California 94143-0544, USA. | lld:pubmed |
| pubmed-article:10848516 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10848516 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:10848516 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10848516 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10848516 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10848516 | lld:pubmed |
